Skip main navigation

Home > Search Results

Main contents starts here

Search Results

41 - 60 of about 405

Total 405 documents found.

  •  
  • Annual Reports
  • A report presenting Takeda’s corporate pilosophy and annual business performance
  • FAQ
  • Frequently Asked Questions (FAQ) This FAQ has been compiled for your convenience.
  • FAQ
  • Frequently Asked Questions (FAQ) This FAQ has been compiled for your convenience.
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Three Months Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 July 31, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: August 11, 2009 1. Consolidated Financial Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Three months ended June 30, 2009 378,977 (4.5) 125,630 137,594 112,594 Three months e
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 21 - 4. Consolidated Financial Statements (1) Consolidated Balance Sheets (Millions of yen) Fiscal 2008 (As of March 31, 2009) Fiscal 2009 (As of March 31, 2010) ASSETS Current assets Cash and deposits 229,533 266,538 Notes and accounts receivable 302,372 280,649 Marketable securities 529,248 616,678 Merchandise and products 60,792 61,120 Work in process 35,327 40,333 Raw materials and supplies 35,539 36,243 Deferred tax assets 218,174 236,236 Other current assets 65,523 36,026 Allowance for doubtful receivables (924) (950) Total current assets 1,475,584 1,572,874 Fixed assets Tangible fixed assets Buildings and structures 103,546 108,007 Machinery, equipment and carriers: 48,079 48,514 Tools and fixtures 8,877 9,920 Land 63,012 62,896 Lease assets 17,026 15,107 Construction in progress 17,954 74,505 Total tangible fixed assets 258,493 318,949 Intangible fixed assets Goodwill 284,446 256,117 Patents 454,137 375,9
  • SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Three Quarters (April 1 to December 31, 2009) of the Fiscal Year Ending March 31, 2010 February 3, 2010 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 15, 2010 Scheduled date of dividend payment commencement: 1. Consolidated Financial Results (April 1 to December 31, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( milli
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction Whole of the pharmaceutical industry has tendency to face a number of challenges, such as stagnation in creating breakthrough novel drugs due to the difficulties of translating new innovations to products in the marketplace, and increasingly strict criteria for the approval of new drugs in advanced countries. Drastic changes in the healthcare systems are underway in many countries, by which it is anticipated that the pharmaceutical industry will be considerably affected. First of all, in the U.S., a bill of healthcare reform which aims to increase the ratio of the insured population was passed. Under the bill, pharmaceutical companies are requested to bear the burden of some portion of funds in order to finance the expansion of available health insurance by increase of the number of po
  • Annual Report 2009 Based on Takeda-ism Relationship with Our Stakeholders CSR Data Book Annual Report 2009 1 CSR Data Book 2 12 14 16 18 20 22 24 26 Relationship with Society Relationship with Environment Relationship with Suppliers Relationship with Employees 8 Quality Assurance System 56 Stakeholders' Voices Employees Who Embody the Takeda-ism Ideals 28 30 32 33 34 36 37 38 40 42 43 44 46 48 50 52 54 4 Scope of Reporting Participating in the United Nations Global Compact Annual Report 2009 - Takeda Pharmaceutical Company Limited Table of Contents Editorial Policy Basic Policy on CSR / CSR Promotion Framework / CSR Activities in Fiscal 2009 Feature Feature: Access to Healthcare in Asia (Activities in Asia) Takeda's Corporate Citizenship Activities Activities in the U.S. Activities in France and Germany Activities in Italy and the UK Activities in Japan and Taiwan Activities in the Philippines and Thailand Other Activities Feature: Supply Chain Management Basic Purchasing Policy / Green Procurement and CSR P
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company", which was set as a target in the 20062010 Medium-term Plan, the Company has been working on various strategies. To achieve this goal, the Company completed a meaningful acquisition and restructuring last year. Firstly, we evenly separated the value of TAP Pharmaceutical Products Inc. ("TAP")a joint venture between Takeda America Holdings, Inc. ("TAH") and Abbott Laboratories ("Abbott") of the U.S.into two companies in April 2008. As part of this company separation, TAP acquired assets related to the already marketed product Prevacid, as well as those related to TAK-390MR (a drug for gastroesophageal reflux disease) and TMX-67 (a drug for hyperuricemia for patients with chronic gout, discovere
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 3 - [Descriptive Information and Financial Statements] 1. Descriptive Information on Consolidated Operating Results (1) Introduction In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company", the Company has been working on the various strategies defined in the 20062010 Medium-term Plan. Of those strategies, with respect to "further strengthening ability to create new drugs", the Company has completed several important transactions this calendar year. Firstly, the acquisition of U.S.-based Millennium Pharmaceuticals Inc. (Millennium) provides Takeda Groupin addition to its own historical strength in research technology that inhibits cancer cell proliferationthe additional strength of Millennium's novel research technology based on inducing cancer cell apoptosis and also provides outstanding clinical development capabilities, both
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 17 - 5. Six-Month Consolidated Financial Statements (April 1 to September 30, 2008) (1) Consolidated Balance Sheets Millions of yen Account As of September 30, 2008 Amount As of March 31, 2008 (summary) Amount ASSETS Current assets Cash and deposits 301,480 239,528 Notes and accounts receivable 339,118 248,189 Marketable securities 497,198 1,445,465 Merchandise 19,354 16,892 Products 36,718 36,540 Semi-finished products 37,167 31,074 Raw materials 31,534 29,718 Work in process 2,732 1,908 Deferred tax assets 201,453 140,962 Other 82,221 54,415 Allowance for doubtful receivables (940) (899) Total current assets 1,548,035 2,243,792 Fixed assets Tangible fixed assets 253,894 236,134 Intangible fixed assets Goodwill 315,639 3,656 Patents 518,065 Other 9,403 6,535 Total intangible fixed assets 843,107 10,191 Investments and other assets Investment securities 260,138 292,
  • FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000088 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market
  • 102 To the Board of Directors of Takeda Pharmaceutical Company Limited: We have audited the accompanying consolidated balance sheet of Takeda Pharmaceutical Company Limited and its consolidated subsidiaries as of March 31, 2008, and the related consolidated statements of income, changes in net assets and cash flows for the year then ended, expressed in Japanese yen. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to independently express an opinion on these consolidated financial statements based on our audit. The consolidated balance sheet of Takeda Pharmaceutical Company Limited and subsidiaries as of March 31, 2007 and the related consolidated statements of income, changes in net assets, and cash flows for each of the two years in the period ended March 31, 2007 were audited by other auditors whose report dated June 28, 2007, expressed an unqualified opinion on those statements with an explanatory paragraph. The explanatory paragraph descri
  • Consolidated Financial Statements for the Fiscal Year Ended March 31, 2007 May 10, 2007 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya 1-1, Doshomachi 4-chome (First section of each) Chuo-ku, Osaka 540-8645, Japan Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Code number: 4502 Representative: Yasuchika Hasegawa, President Contact: Toyoji Yoshida, Director, Corporate Communications Department Tel: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 28, 2007 Scheduled date of securities report submission: June 28, 2007 Scheduled date of dividend payment commencement: June 29, 2007 1. Consolidated Results for Fiscal 2006 (April 1, 2006 - March 31, 2007) (1) Sales and Income All amounts are rounded to the nearest million yen. Percentage figures represent changes from previous year. Net sales ( million)
  • Consolidated Financial Statements for the Interim Period of Fiscal 2006 November 6, 2006 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya (First Section of each), 1-1, Doshomachi 4-chome Fukuoka, Sapporo Chuo-ku, Osaka 540-8645, Japan Code number: 4502 URL: http://www.takeda.co.jp/ Board of Directors meeting: November 6, 2006 Representative: Yasuchika Hasegawa, President Use of U.S. accounting standards: No Contact: Toyoji Yoshida, Director Telephone: +81-6-6204-2060, +81-3-3278-2039 1. Results for the Interim Period of Fiscal 2006 (April 1, 2006-September 30, 2006) (1) Consolidated Operating Results (All amounts are rounded to the nearest million yen.) Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Interim period of fiscal 2006
  • Consolidated Financial Statements for the Interim Period of Fiscal 2005 November 4, 2005 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya (First Section of each), 1-1, Doshomachi 4-chome Fukuoka, Sapporo Chuo-ku, Osaka 540-8645, Japan Code number: 4502 URL: http://www.takeda.co.jp/ Board of Directors meeting: November 4, 2005 Representative: Yasuchika Hasegawa, President and COO Use of U.S. accounting standards: No Contact: Toyoji Yoshida, Director Telephone: +81-6-6204-2060, +81-3-3278-2039 1. Results for the Interim Period of Fiscal 2005 (April 1, 2005-September 30, 2005) (1) Sales and Income All amounts are rounded to the nearest million yen. Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Interim period of fiscal 2005 Interim
  • - 1 - Consolidated Financial Statements for the Fiscal Year Ended March 31, 2006 May 11, 2006 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya 1-1, Doshomachi 4-chome (First section of each) Chuo-ku, Osaka 540-8645, Japan Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Code number: 4502 Representative: Yasuchika Hasegawa, President and COO Board of Directors meeting: May 11, 2006 Contact: Toyoji Yoshida, Director Use of U.S. accounting standards: No Tel: +81-6-6204-2060 +81-3-3278-2039 1. Results for Fiscal 2005 (April 1, 2005 - March 31, 2006) (1) Sales and Income All amounts are rounded to the nearest million yen. Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Fiscal 2005 Fiscal 2004 1,212,207 1,122,960 7.9 3.4 402,809 385,278
  • FFiinnaanncciiaall RReessuullttss ffoorr 11st HHaallff FFYY22000055st DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2039 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/english/financial/index.html [Takeda-ism] We, the members of the Takeda Group, pledge to act with integrity at all times, especially when facing difficulties or challenges. "Integrity" refers to our compliance with the highest ethical standards, our fairness and honesty in conducting every activity, and our perseverance in pursuing the ideal forms for our operations and management. Through the demonstration of these qualities, we show our commitment to building trust and confidence in all the people around us, and our determination to continue to expand the business. These empower our progress in our global endeavors to fulfill our mission to "strive toward better health for individuals and progress in medicine by developing superior pha
  • FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000055 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2039 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html [Takeda-ism] We, the members of the Takeda Group, pledge to act with integrity at all times, especially when facing difficulties or challenges. "Integrity" refers to our compliance with the highest ethical standards, our fairness and honesty in conducting every activity, and our perseverance in pursuing the ideal forms for our operations and management. Through the demonstration of these qualities, we show our commitment to building trust and confidence in all the people around us, and our determination to continue to expand the business. These empower our progress in our global endeavors to fulfill our mission to "strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products." 2

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top